Literature DB >> 7268921

The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG.

G A Rook, G M Bahr, J L Stanford.   

Abstract

The previous paper presents evidence that prior exposure to some environmental mycobacteria enhances the protective efficacy of BCG, whereas exposure to other species opposes it, and suggests that these different species act by evoking one of two types of cell-mediated response of different protective efficacy. This paper reviews past evidence for the existence of these two types of response, and suggests that both can be demonstrated in mice. The type of response evoked in mice by environmental species correlates with their effect on the efficacy of BCG in man, and with the type of proliferative response evoked in human peripheral blood lymphocytes by their soluble antigens in vitro. Preimmunisation of mice to give one type of response can block subsequent induction of the other. We therefore present a model, based on this principle, for the interaction of contact with environmental mycobacteria with subsequent BCG vaccination.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7268921     DOI: 10.1016/0041-3879(81)90038-6

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  15 in total

1.  Measurements of blood flow and histometry of the cellular infiltrate in tuberculin skin test responses of the typical Koch type and the non-turgid variant form (Listeria-type) in pulmonary tuberculosis patients and apparently healthy controls.

Authors:  R C Potts; J S Beck; J H Gibbs; J M Grange; T Kardjito; J L Stanford
Journal:  Int J Exp Pathol       Date:  1992-10       Impact factor: 1.925

2.  Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Authors:  Lise Brandt; Joana Feino Cunha; Anja Weinreich Olsen; Ben Chilima; Penny Hirsch; Rui Appelberg; Peter Andersen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis.

Authors:  Suraj B Sable; Rajnish Kumar; Mamta Kalra; Indu Verma; G K Khuller; Karen Dobos; John T Belisle
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 4.  The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link?

Authors:  F Abebe; G Bjune
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

Review 5.  Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.

Authors:  Hansong Chae; Sung Jae Shin
Journal:  J Microbiol       Date:  2018-05-02       Impact factor: 3.422

6.  Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria.

Authors:  I M Orme; F M Collins
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

7.  Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy.

Authors:  P J Converse; A M Dannenberg; T Shigenaga; D N McMurray; S W Phalen; J L Stanford; G A Rook; T Koru-Sengul; H Abbey; J E Estep; M L Pitt
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

8.  BCG vaccination of children against leprosy in Uganda: final results.

Authors:  S J Stanley; C Howland; M M Stone; I Sutherland
Journal:  J Hyg (Lond)       Date:  1981-10

Review 9.  Manipulation of BCG vaccine: a double-edged sword.

Authors:  V K Singh; R Srivastava; B S Srivastava
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-25       Impact factor: 3.267

10.  HLA-DR3 associated genetic control of response to multiple skin tests with new tuberculins.

Authors:  W van Eden; R R de Vries; J L Stanford; G A Rook
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.